Gene Therapy for Myocardial Infarction: A Real Medicine in the Next Millenium?

Heart Failure ◽  
2000 ◽  
pp. 219-226
Author(s):  
Ryuichi Morishita ◽  
Motokuni Aoki ◽  
Hidenori Nakagami ◽  
Yoshiaki Taniyama ◽  
Kei Yamamoto ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Gene Therapy

scholarly journals Elabela gene therapy promotes angiogenesis after myocardial infarction

2021 ◽  
Author(s):  
Liangli Jin ◽  
Yang Pan ◽  
Quanyi Li ◽  
Jing Li ◽  
Zhi Wang
Keyword(s):  
Myocardial Infarction ◽  
Gene Therapy

scholarly journals Cardiovascular gene therapy for myocardial infarction

2013 ◽  
Vol 14 (2) ◽  
pp. 183-195 ◽  
Author(s):  
Maria C Scimia ◽  
Anna M Gumpert ◽  
Walter J Koch
Keyword(s):  
Myocardial Infarction ◽  
Gene Therapy

Abstract 870: Cardiac Gene Therapy With Relaxin Receptor 1 Overexpression Protects Against Acute Myocardial Infarction and Associated Adverse Remodeling

2019 ◽  
Vol 125 (Suppl_1) ◽  
Author(s):  
Teja Devarakonda ◽  
Erik Kohlbrenner ◽  
Adolfo G Mauro ◽  
Chad Cain ◽  
Anindita Das ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Gene Therapy ◽  
Cardiac Gene ◽  
Adverse Remodeling ◽  
Relaxin Receptor

Gene Therapy for Myocardial Infarction

2007 ◽  
pp. 531-544
Author(s):  
Ryuichi Morishita ◽  
Motokuni Aoki ◽  
Hidetsugu Matsushita ◽  
Yasufumi Kaneda ◽  
Jitsuo Higaki ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Gene Therapy

scholarly journals 297. The Influence of ELABELA AAV Gene Therapy on Cardiorenal Function in Rat Models of Salt-Induced Hypertension and Myocardial Infarction

2016 ◽  
Vol 24 ◽  
pp. S119
Author(s):  
Claire A. Schreiber ◽  
Sara Holditch ◽  
Alex Generous ◽  
Yasuhiro Ikeda
Keyword(s):  
Myocardial Infarction ◽  
Gene Therapy ◽  
Rat Models ◽  
Induced Hypertension

scholarly journals Ex Vivo Akt/HO-1 Gene Therapy to Human Endothelial Progenitor Cells Enhances Myocardial Infarction Recovery

2012 ◽  
Vol 21 (7) ◽  
pp. 1443-1461 ◽  
Author(s):  
Keith R. Brunt ◽  
Jun Wu ◽  
Zhilin Chen ◽  
Daniel Poeckel ◽  
Ryan A. Dercho ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Gene Therapy ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Ex Vivo ◽  
Endothelial Progenitor

Gene therapy knockdown of Hippo signaling induces cardiomyocyte renewal in pigs after myocardial infarction

2021 ◽  
Vol 13 (600) ◽  
pp. eabd6892
Author(s):  
Shijie Liu ◽  
Ke Li ◽  
Leonardo Wagner Florencio ◽  
Li Tang ◽  
Todd R. Heallen ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Gene Therapy ◽  
Viral Vector ◽  
Left Ventricular ◽  
Border Zone ◽  
High Dose ◽  
Cell Renewal ◽  
Hippo Signaling ◽  
Lung Pathology

Human heart failure, a leading cause of death worldwide, is a prominent example of a chronic disease that may result from poor cell renewal. The Hippo signaling pathway is an inhibitory kinase cascade that represses adult heart muscle cell (cardiomyocyte) proliferation and renewal after myocardial infarction in genetically modified mice. Here, we investigated an adeno-associated virus 9 (AAV9)–based gene therapy to locally knock down the Hippo pathway gene Salvador (Sav) in border zone cardiomyocytes in a pig model of ischemia/reperfusion-induced myocardial infarction. Two weeks after myocardial infarction, when pigs had left ventricular systolic dysfunction, we administered AAV9-Sav–short hairpin RNA (shRNA) or a control AAV9 viral vector carrying green fluorescent protein (GFP) directly into border zone cardiomyocytes via catheter-mediated subendocardial injection. Three months after injection, pig hearts treated with a high dose of AAV9-Sav-shRNA exhibited a 14.3% improvement in ejection fraction (a measure of left ventricular systolic function), evidence of cardiomyocyte division, and reduced scar sizes compared to pigs receiving AAV9-GFP. AAV9-Sav-shRNA–treated pig hearts also displayed increased capillary density and reduced cardiomyocyte ploidy. AAV9-Sav-shRNA gene therapy was well tolerated and did not induce mortality. In addition, liver and lung pathology revealed no tumor formation. Local delivery of AAV9-Sav-shRNA gene therapy to border zone cardiomyocytes in pig hearts after myocardial infarction resulted in tissue renewal and improved function and may have utility in treating heart failure.

Sign in / Sign up

Export Citation Format

Share Document